Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial

Abstract Background Recent cardiovascular outcome trials have shown significant reductions in major (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for risk validated by some studies include arterial stiffness and endothelial function indexes. To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on indexes surrogate markers vascular damage. Aims We aimed to evaluate metabolic efficacy endpoints once-weekly dulaglutide (1.5 mg) plus traditional treatment compared alone subjects type 2 diabetes. Methods Men women (aged ? 50 years) established or newly detected diabetes whose HbA1c level was 9.5% less stable doses up two oral glucose­ lowering without basal insulin therapy were eligible randomization. Subcutaneous initiated at full dose mg/day weekly). Arterial (PWV: pulse wave velocity augmentation index) (RHI: reactive hyperaemia evaluated baseline three-month nine-month examination visits. At each visit (at 3 9 months), also glycaemic variables fasting plasma glucose (FPG) lipid total cholesterol, LDL HDL cholesterol triglyceride levels. Results follow-up, treated showed significantly lower serum levels FPG than control conventional therapy. 9-month values mean diastolic blood pressure, BMI, FPG, PWV higher RHI Conclusions Our that 1.5 subcutaneous favourable associated positive health markers. These findings are consistent previous study indicating strict relationship between factors systolic